Endosense raises $36 million
Endosense, a Geneva, Switzerland-based med-tech company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has raised $36 million in Series B funding.
Endocyte Inc., a developer of drugs for ovarian and lung tumors, raised $75 million in its initial public offering after cutting the price twice this week for a total reduction of as much as 60 percent.